Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07777575 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Resistance Training to Prevent Muscle Loss During Treatment With Tirzepatide

Study acronym: RESIST
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened Show 5 more changesShow less
    • Start date: Aug 17, 2026 to Sep 7, 2026
    • Interventions: Dual GIP/GLP-1 Receptor Agonist Tirzepatide (Drug), Resistance Training (Behavioral) to Dual GIP/GLP-1 Receptor Agonist Tirzepatide (Drug), Resistance Training (Behavioral)
    • Eligibility criteria expanded, about 55 words
    • Secondary endpoints: details revised at 4 of 21 entries
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Incretin-based pharmacotherapies induce significant weight loss and represent a paradigm shift in obesity treatment. However, particularly fast weight loss may be accompanied by a significant loss of muscle mass, which is associated with a reduced metabolic rate at rest and during physical activity, increased insulin resistance, limited mobility, and potential long-term adverse effects. The aim of this clinical trial is to examine the effects of resistance training versus standard of care on contractile thigh muscle volume in patients receiving the dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists 'tirzepatide'.
Trial Details
NCT Number NCT07777575
Lead Sponsor Technical University of Munich
Collaborators: EGYM SE
Conditions
(from sponsor)		 Obesity (BMI>30)
Related terms Obesity, Weight Loss
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov